The panel went against the conclusions of the agency’s career scientists, who said there wasn’t enough evidence to support the move. The panel went against the conclusions of the agency’s career scientists, who said there wasn’t enough evidence to support the move.
FDA panel recommends easing restrictions on several peptidesFDA panel recommends easing restrictions on several peptides
